Managing traditional cardiovascular risk factors with a treat-to-target approach slows progression of subclinical atherosclerosis among patients with rheumatoid arthritis, suggest results from the FRANCIS trial.
In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.
Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.
Mycophenolate mofetil is noninferior to cyclophosphamide for inducing remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, randomized trial data show.
Source:
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-214245
Managing traditional cardiovascular risk factors with a treat-to-target approach slows progression of subclinical atherosclerosis among patients with rheumatoid arthritis, suggest results from the FRANCIS trial.
Source:
Ann Rheum Dis 2019; doi:10.1136/annrheumdis-2018-214075
Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.
Demographic factors, measures of disease activity, and the type of treatment used are associated with 2-year outcomes among patients with juvenile idiopathic arthritis-associated uveitis, according to findings from the ICON-JIA study.
Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.
Study findings do not support the use of one non-tumor necrosis factor inhibitor biologic DMARD over another when considering the risk for serious infection in patients with rheumatoid arthritis.
Source:
Ann Rhuem Dis 2018; doi:10.1136/annrheumdis-2018-214326
